DMK Pharmaceuticals Corporation, along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on February 2, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, U.S. Compounding, Inc., Rhombus Pharmaceuticals Corporation, Biosyn, Inc. and Adamis Corporation, with its own case for administrative and procedural purposes. DMK Pharmaceuticals Corporation has been proposed as the lead debtor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.03 USD | +3.45% | 0.00% | -95.72% |
May. 08 | Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation | CI |
Apr. 11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
1st Jan change | Capi. | |
---|---|---|
-95.72% | 303K | |
+35.01% | 709B | |
+30.54% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.00% | 239B | |
+9.21% | 211B | |
-3.35% | 203B | |
+10.77% | 171B |
- Stock Market
- Equities
- DMKPQ Stock
- News DMK Pharmaceuticals Corporation
- Motion for Joint Administration Filed by DMK Pharmaceuticals Corporation